CLINICAL TRIALS PROFILE FOR PORTRAZZA

All Clinical Trials for PORTRAZZA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02496663 ↗	Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor	Active, not recruiting	National Cancer Institute (NCI)	Phase 1	2016-03-24	This phase I trial studies the side effects and best dose of necitumumab when given together with osimertinib in treating patients with EGFR-mutant non-small cell lung cancer that is stage IV or has come back (recurrent) and who have progressed on a previous EGFR tyrosine kinase inhibitor. Immunotherapy with monoclonal antibodies, such as necitumumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving necitumumab with osimertinib may be a better treatment for EGFR-mutant non-small cell lung cancer.
NCT03944772 ↗	Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)	Recruiting	AstraZeneca	Phase 2	2019-06-25	Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer who progressed on First-Line Osimertinib Therapy. This study is modular in design, allowing evaluation of the efficacy, safety and tolerability of multiple study treatments.
NCT04285671 ↗	Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer	Recruiting	Eli Lilly and Company	Phase 1/Phase 2	2021-01-29	This phase Ib/II trial studies the side effects and best dose of trastuzumab and necitumumab together with osimertinib, and to see how well they work for the treatment of stage IV non-small cell lung cancer that is EGFR-mutated, resistant to osimertinib, and has not responded to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as trastuzumab and necitumumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving trastuzumab and necitumumab together with osimertinib may work better than osimertinib alone in treating patients with stage IV EGFR-mutated non-small cell lung cancer.
NCT04285671 ↗	Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer	Recruiting	Genentech, Inc.	Phase 1/Phase 2	2021-01-29	This phase Ib/II trial studies the side effects and best dose of trastuzumab and necitumumab together with osimertinib, and to see how well they work for the treatment of stage IV non-small cell lung cancer that is EGFR-mutated, resistant to osimertinib, and has not responded to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as trastuzumab and necitumumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving trastuzumab and necitumumab together with osimertinib may work better than osimertinib alone in treating patients with stage IV EGFR-mutated non-small cell lung cancer.
NCT04285671 ↗	Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer	Recruiting	National Cancer Institute (NCI)	Phase 1/Phase 2	2021-01-29	This phase Ib/II trial studies the side effects and best dose of trastuzumab and necitumumab together with osimertinib, and to see how well they work for the treatment of stage IV non-small cell lung cancer that is EGFR-mutated, resistant to osimertinib, and has not responded to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as trastuzumab and necitumumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving trastuzumab and necitumumab together with osimertinib may work better than osimertinib alone in treating patients with stage IV EGFR-mutated non-small cell lung cancer.
NCT04285671 ↗	Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer	Recruiting	Jonsson Comprehensive Cancer Center	Phase 1/Phase 2	2021-01-29	This phase Ib/II trial studies the side effects and best dose of trastuzumab and necitumumab together with osimertinib, and to see how well they work for the treatment of stage IV non-small cell lung cancer that is EGFR-mutated, resistant to osimertinib, and has not responded to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as trastuzumab and necitumumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving trastuzumab and necitumumab together with osimertinib may work better than osimertinib alone in treating patients with stage IV EGFR-mutated non-small cell lung cancer.

Clinical Trial Conditions for PORTRAZZA

Condition Name

Condition Name for PORTRAZZA
Intervention	Trials
Metastatic Lung Non-Small Cell Carcinoma	2
Refractory Lung Non-Small Cell Carcinoma	1
Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8	1
Stage IV Lung Non-Small Cell Cancer AJCC v7	1

Condition MeSH

Condition MeSH for PORTRAZZA
Intervention	Trials
Lung Neoplasms	3
Carcinoma, Non-Small-Cell Lung	3
Carcinoma	2

Clinical Trial Locations for PORTRAZZA

Trials by Country

Trials by Country for PORTRAZZA
Location	Trials
United States	17
Korea, Republic of	1
Spain	1
Japan	1
Norway	1

Trials by US State

Trials by US State for PORTRAZZA
Location	Trials
California	3
Massachusetts	2
Washington	1
Texas	1
New York	1

Clinical Trial Progress for PORTRAZZA

Clinical Trial Phase

Clinical Trial Phase for PORTRAZZA
Clinical Trial Phase	Trials
Phase 2	1
Phase 1/Phase 2	1
Phase 1	1

Clinical Trial Status

Clinical Trial Status for PORTRAZZA
Clinical Trial Phase	Trials
Recruiting	2
Active, not recruiting	1

Clinical Trial Sponsors for PORTRAZZA

Sponsor Name

Sponsor Name for PORTRAZZA
Sponsor	Trials
National Cancer Institute (NCI)	2
AstraZeneca	1
Eli Lilly and Company	1

Sponsor Type

Sponsor Type for PORTRAZZA
Sponsor	Trials
Industry	3
NIH	2
Other	1

Last updated: May 17, 2026

Portrazza (necitumumab) Clinical Trials Update, Market Analysis, and Exclusivity Timelines: What to Know for R&D, Licensing, and Generic Risk

Executive summary: Portrazza (necitumumab) is an epidermal growth factor receptor (EGFR) blocking monoclonal antibody used in combination with chemotherapy for advanced squamous non-small cell lung cancer (sqNSCLC). The clinical and commercial thesis is tied to the first-line advanced sqNSCLC setting after a phase 3 result that established benefit in combination use. The forward view for market opportunity depends on (1) continued guideline uptake in the eligible population, (2) durability of response and sequencing against newer regimens, and (3) the availability and pace of biosimilar entry where applicable to biologics regulatory exclusivity and patent protection.

The analysis below covers trial signal context, commercialization benchmarks that inform revenue modeling, and an exclusivity and competitive landscape framework relevant for generic and biosimilar risk.

---

What is Portrazza (necitumumab) used for and what patient populations drive uptake?

Label use (core commercial indication):

• Advanced or metastatic sqNSCLC in the first-line setting, in combination with gemcitabine and cisplatin.
• The drug is positioned for patients whose disease fits the histology and stage criteria of the pivotal trial.

Commercial implication

• Uptake is constrained by (i) sqNSCLC proportion within NSCLC, and (ii) eligibility for platinum doublet + anti-EGFR mAb in first-line workflows.

Which biomarkers or clinical criteria influence eligibility?

• Necitumumab is an EGFR-targeting antibody; clinical selection in practice is generally anchored on histology (squamous) and advanced-stage treatment setting rather than a single mandatory biomarker test across geographies.

How does Portrazza fit against immunotherapy standard-of-care?

• The competitive battleground in advanced sqNSCLC has shifted toward checkpoint inhibitor (CPI) combinations. Portrazza’s current commercial traction depends on whether it retains use in specific segments where chemotherapy plus targeted therapy remains preferred or where dosing schedules align with payer coverage and protocol preferences.

---

What clinical trials support Portrazza and what is the latest development direction?

Pivotal evidence basis

• Approval was grounded in the phase 3 development program assessing necitumumab + gemcitabine/cisplatin versus chemotherapy alone in advanced sqNSCLC.

What key endpoints drove adoption?

• Overall survival (OS) and progression-free survival (PFS) were central.
• A survival benefit at the population level supported guideline inclusion in certain settings.

What safety profile affects switching behavior?

• EGFR-pathway blockade class safety issues include skin toxicities, electrolyte abnormalities, and infusion-related events.
• Real-world uptake can be affected by toxicity management capacity and clinician comfort, especially when PD-1/PD-L1 regimens are the default first-line option.

What is the likely current clinical development posture?

• In most jurisdictions, established biologics with limited new registrational trial programs shift from “expansion” to “life-cycle” strategies: dosing refinement, subgroup analysis, combination exploration, and real-world evidence.
• Portrazza’s market headwinds in sqNSCLC have generally intensified as CPI regimens became standard first-line, leaving smaller niches for targeted monoclonal approaches.

---

Which patents protect Portrazza (necitumumab) and how strong is the patent estate for exclusivity?

Patent architecture drivers for a biologic

• Typical estates for mAbs include:
  1. composition-of-matter for the antibody (sequence- and epitope-specific),
  2. formulation and stable dosage form,
  3. methods of use (patient population and line of therapy),
  4. manufacturing processes and intermediates.

Actionable exclusivity risk frame

• For biosimilar planning, the controlling question is not only patent expiry but also whether the estate is “layered”:
  • multiple independent composition claims,
  • method-of-use claims tied to the exact label population,
  • and packaging/formulation protection that can block certain product designs.

How to evaluate patent strength in Portrazza biosimilar planning

• Prioritize mapping of:
  • granted claims covering antibody structure or binding function,
  • label-mirroring method claims in first-line advanced sqNSCLC,
  • and any process claims that can be designed around.

(Note: this section requires Orange Book/Biologics License Application patent list data to name specific US patents and expiration dates, which are not provided in the request.)

---

When does Portrazza lose exclusivity and when do biosimilars/generics become possible?

Two timelines matter

• Regulatory exclusivity for biologics (data exclusivity and related protections depending on approval pathway).
• Patent expiry (plus any pediatric exclusivity extensions and litigation or settlement tolling).

What is the practical entry window concept?

• A biosimilar can pursue the pathway only when it can certify non-infringement or invalidity for the listed patents, and only after the barriers tied to those patents clear, through:
  • expiration,
  • settlement,
  • or litigation outcome.

(Note: specific dates require the FDA “Purple Book” listing for neci­tumumab biosimilar-related patents or the equivalent exclusivity record, which are not supplied in the prompt.)

---

What is the Orange Book status of Portrazza and what does it mean for Paragraph IV challenges?

Portrazza is a biologic monoclonal antibody, not a small-molecule product. Paragraph IV certifications and the Orange Book framework are typically relevant to FDA-approved small-molecule drugs under Hatch-Waxman. For biologics, the analogous reference is the FDA “Purple Book” and biosimilar-related patent listings.

Commercial planning implication

• If there is no Orange Book listing for the product, a Paragraph IV-based generic strategy is usually not the correct risk model.
• Biosimilar entry planning should center on Purple Book-listed patents and BLA biosimilar pathways.

(Note: without FDA listing data in the request, this cannot be completed with product-specific patent status.)

---

What patent litigation affects Portrazza and what settlement terms would matter?

For mAb assets, litigation can shape:

• entry dates through settlement-triggered “design around” or launch-stagger agreements,
• exclusivity preservation by extending effective patent blocking,
• and additional stays tied to appeal timelines.

What to look for in Portrazza litigation records

• filings by biosimilar sponsors,
• counterclaims on validity and infringement,
• and the date of any final judgments or consent decrees.

(Note: litigation specifics and docket references require case data not included in the request.)

---

How does Portrazza compare with competing treatments for advanced squamous NSCLC?

Primary comparators

• platinum-based chemotherapy standards.
• immune checkpoint inhibitors (CPI) and CPI plus chemotherapy regimens.
• other EGFR-targeting strategies used in squamous histology depending on region and guideline.

Commercial differentiation levers

• Clinical position: first-line eligibility and sequencing with CPI.
• Administration burden: infusion schedule and required monitoring.
• Payer policy: whether the combination is reimbursed at parity with immunotherapy or relegated after CPI failure.

Market share outcome logic

• In a setting where CPI becomes predominant, a targeted mAb that requires chemotherapy pairing often experiences protocol displacement unless it retains a distinct benefit in an identifiable subgroup or maintains payer support.

---

What is the market analysis for Portrazza and how should revenue projections be modeled?

Revenue driver structure (inputs)

1. Diagnosed population for advanced sqNSCLC.
2. Treatment line penetration (first-line combination share).
3. Duration of therapy and average dose intensity.
4. Net price after rebates, discounts, and payer contracting.
5. Switching and discontinuation due to toxicity or protocol changes.
6. Competition from CPI regimens and other targeted agents.
7. Geographic mix (US/EU/ROW) and reimbursement differences.

Projection scenarios

A practical modeling framework uses three cases:

• Base case: continued but modest share retention within sqNSCLC first-line chemotherapy combination segments.
• Downside case: accelerating displacement by CPI-chemotherapy dominance and reduced chemotherapy-only space.
• Upside case: renewed uptake if sequencing evidence supports benefit or if payers reinstate targeted mAb coverage in eligible patients.

Key market risks

• protocol shifts to CPI regimens,
• safety management friction,
• and limited life-cycle expansion that reduces incremental uptake.

(Note: numeric market size and forecasts require access to sales datasets, pricing, and regional adoption data which are not included.)

---

What generic entry risks exist for Portrazza and how do biosimilar hurdles differ by region?

Biologics-specific entry model

• Biosimilar developers face:
  • patent list challenges and litigation,
  • manufacturing comparability and clinical bridge requirements,
  • pharmacovigilance commitments.

Regional variability

• US: Purple Book patents and BLA biosimilar pathway; patent litigation is central.
• EU: EMA biosimilar framework and national payer decisions influence uptake post-approval.
• Other markets: IP enforcement and regulatory speed vary, affecting the timing of commercial entry.

(Note: biosimilar competitors and timeline depend on registration and patent landscapes that are not provided.)

---

What formulations are protected for Portrazza and do manufacturing choices create design-around space?

Typical protected elements for mAbs

• liquid formulation composition for stability (buffer, pH, tonicity agents),
• surfactant systems to prevent aggregation,
• container closure system compatibility,
• process parameters that impact CQAs such as particle counts and glycosylation profiles.

How manufacturing affects IP risk

• If process claims exist, biosimilar sponsors may need to demonstrate:
  • different upstream/downstream steps,
  • different purification or filtration schemes,
  • or compliance with distinct process windows.

(Note: protected formulation/process specifics require the patent list.)

---

What method-of-use patents matter for Portrazza’s label and how do they constrain biosimilar design?

Method-of-use bottlenecks

• In mAb ecosystems, the label population (advanced sqNSCLC, line of therapy, and combination regimen) is often the claim target.
• If method-of-use claims are robust, biosimilars can be delayed even if they can navigate composition claims.

Claim-construction sensitivity

• Small differences in:
  • histology definitions,
  • regimen combinations,
  • treatment line definitions,
  • and patient selection criteria can alter infringement outcomes.

(Note: method-of-use patent numbers and scope are not available in the prompt.)

---

Key Takeaways

• Portrazza (necitumumab) is commercially anchored to advanced sqNSCLC and is positioned as a combination regimen tied to specific first-line workflows.
• Market outlook is primarily a function of protocol displacement risk from CPI-centered regimens and the drug’s ability to maintain reimbursement and clinician preference.
• Exclusivity and biosimilar entry are governed by biologics-specific patent listings and regulatory exclusivity, not Orange Book Paragraph IV frameworks.
• The decisive variable for biosimilar timing is the layered patent stack across composition, method-of-use, and formulation/manufacturing claims, plus litigation settlement dynamics.

---

FAQs

1. Is Portrazza covered by biosimilar exclusivity protections, and how does that differ from small-molecule generic entry?
2. Which factors most influence Portrazza prescribing in advanced squamous NSCLC: histology, line of therapy, or biomarker status?
3. How does Portrazza’s safety profile affect real-world persistence compared with chemotherapy alone?
4. What is the most common mechanism of biosimilar launch delay for monoclonal antibodies like Portrazza?
5. What sequencing strategies against checkpoint inhibitors can preserve targeted antibody combination use?

---

References (APA)

1. FDA. (n.d.). Purple Book: Lists of Licensed Biological Products. U.S. Food and Drug Administration.
2. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.